EUVIMEDEUVIMED entdecken
Crossref

L26/P-737 Role of human umbilical cord blood and placental mesenchymal stem cells in treating premature ovarian insufficiency for in vitro fertilization program

A. Feskova, O. Feskov, Y. Zhylkova, I. Feskova, L. Konoplia, K. Kovalenko

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Feskova und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does treatment with umbilical cord blood and placenta-derived products improve clinical outcomes of IVF in women with premature ovarian insufficiency? Summary answer Umbilical cord blood and placental preparations have demonstrated the ability to restore ovarian function in women with premature ovarian insufficiency. What is known already Premature ovarian insufficiency (POI) is one of the conditions that lead to female infertility, where traditional or conventional treatments have limited efficacy. Premature ovarian insufficiency patients experience a decline in ovarian reserve and a disruption in serum reproductive hormones, leading to a significant impact on the outcomes of assisted reproductive technology. Human umbilical cord (hUC) blood and placenta mesenchymal stem cells have emerged as promising therapeutic alternatives in regenerative medicine. Within the female reproductive tract, the ovary is the organ most commonly treated with hUC cells. Study design, size, duration Totally 63 infertile patients with diagnosis “Premature ovarian insufficiency” proved by the follicle number and by the levels of hormones (follicle-stimulating hormone (FSH), anti-Müllerian hormone (AMH) and estradiol (E2)) underwent the treatment of POI in period December 2024 to December 2025. Participants/materials, setting, methods POI women were divided into 2 groups. Group 1: 35 POI-patients, 40.9±2,9 y.o. The standard IVF protocol with previous subcutaneous administration of human placenta fragments and human cord blood preparations injection was applied in Group 1. Group 2: 28 POI-women, 39.7±3.6 y.o. Standard IVF protocol was applied in Group 2. Antral follicles count and the levels of E2 and FSH before and after the 90 days of the treatment were compared in mentioned Groups. Main results and the role of chance Antral follicles count (AFC) in both ovaries visible on ultrasound differed from 0 to 3 in total POI-group before the treatment. After the 90 days of the surveillance the AFC was higher in 54,2% of patients in Group 1. The average AFC in Group 1-patients was higher after the treatment (5.6±3.63 vs. 2.25±1.63, P < 0.05). The number of oocytes retrieved per IVF cycle was significantly higher in group 1 compared with group 2 and amounted to 4.48 ± 3.52 versus 2.5 ± 1.57, respectively (p < 0.05). Similarly, the number of mature (MII) oocytes per IVF cycle was significantly higher in group 1, reaching 3.53 ± 2.66, compared with 2.0 ± 1.42 in group 2 (p < 0.05). The clinical pregnancy rate was also higher in group 1 (17.85%) compared with group 2 (11.40%), indicating improved reproductive outcomes in patients receiving the treatment with umbilical cord blood and placenta-derived products (p < 0.05). In Group 2 only in 10.7% of women the AFC was higher after the standard treatment. The average AFC didn’t change in Group 2-patients. There were no significant changes in the E2 and FSH levels for women in both Groups. Limitations, reasons for caution Women over 45 years of age were excluded from the study. The relatively small sample size and the single-center design may limit the generalizability of the findings. Larger multicenter randomized controlled trials are needed to confirm these results. Wider implications of the findings Human umbilical cord blood and placental stem cell therapy may represent a promising adjunctive treatment for infertility in patients with premature ovarian insufficiency. The use of regenerative medicine in combination with ART could improve reproductive outcomes in this challenging patient population. Trial registration number Yes

Zitieren

APA

Feskova, A., Feskov, O., Zhylkova, Y., Feskova, I., Konoplia, L., & Kovalenko, K. (2026). L26/P-737 Role of human umbilical cord blood and placental mesenchymal stem cells in treating premature ovarian insufficiency for in vitro fertilization program. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1064

Vancouver

Feskova A, Feskov O, Zhylkova Y, Feskova I, Konoplia L, Kovalenko K. L26/P-737 Role of human umbilical cord blood and placental mesenchymal stem cells in treating premature ovarian insufficiency for in vitro fertilization program. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1064

BibTeX
@article{Feskova2026,
  author = {Feskova, A. and Feskov, O. and Zhylkova, Y. and Feskova, I. and Konoplia, L. and Kovalenko, K.},
  title = {L26/P-737 Role of human umbilical cord blood and placental mesenchymal stem cells in treating premature ovarian insufficiency for in vitro fertilization program},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1064}
}
Kostenlos starten →